N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Not applicable ClinicalTrials.gov

The Multicenter Stress Cardiac Magnetic Resonance Quantitative Perfusion Imaging in the United States Study

Sponsor: Brigham and Women's Hospital • ClinicalTrials.gov ID: NCT06854458

Registry updated: 2026-09-01
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

This research aims to investigate whether symptoms of chest pain or shortness of breath among the study population are arising due to a heart problem, particularly any reduction of blood flow to the heart muscle from blockages in the coronary blood vessels or inflammation of the heart using cardiac magnetic resonance imaging that measures the amount of blood flow during a stress state meant to simulate vigorous exercise. At present, doctors use standard magnetic resonance imaging pictures of blood flow patterns to treat heart disease. The investigators want to study if detailed blood flow measurements, in addition to the standard blood flow pattern, could diagnose heart disease more accurately and allow more doctors to understand the severity of heart disease. Early research has demonstrated that detailed blood flow measurements may be more accurate in diagnosing heart disease in some patients, but doctors need more information to know how to use these measurements.

Interventions

  • Quantitative Myocardial Blood Flow Evaluation (Diagnostic test)
    The perfusion sequence will produce on-the-fly additional quantitative perfusion maps with segmental myocardial blood flow values.
  • Qualitative Myocardial Blood Flow Evaluation (Diagnostic test)
    The perfusion sequence will not produce additional quantitative perfusion maps.
  • Gadavist (Drug)
    Participants will receive Gadavist 0.05 mmol/kg dose for each stress and rest perfusion imaging (total dose of 0.1 mmol/kg).
  • Vasodilator (Drug)
    All participants will receive vasodilator (regadenoson or adenosine depending on local site practice).
  • Blood draw for the laboratory assessment (Diagnostic test)
    A single (7-10 ml tube) whole blood sample will be collected from each patient for processing of blood biomarkers.

Eligibility criteria

Inclusion Criteria: 1. male or female at age 35-85 years, 2. presence of either of the following sign/symptom that led to a referral to stress cardiac magnetic resonance imaging: 1. chest pain or anginal equivalent, or 2. abnormal electrocardiogram with a suspicion of coronary artery disease 3. Intermediate or high risk of significant coronary disease based on at least 1 of the following conditions: a) patient age \> 45 for male, 50 for female b) Diabetes, hypertension, or hypercholesterolemia: by either history or medical treatment c) family history of premature coronary disease: first degree relative at age \<= 55 male and \<=65 female d) history of smoking of \> 10 packed-years e) post-menopausal state \>5 years f) any chronic inflammatory conditions d) Body mass index \> 30 e) Any medical documentation of coronary or peripheral artery disease Exclusion Criteria: 1. Acute myocardial infarction within the past 30 days prior to cardiac magnetic resonance imaging 2. Confirmed diagnosis of any significant non-coronary cardiac conditions below: 1. any severe-grade valvular heart disease, 2. left ventricular ejection fraction \<40% from any known non-coronary causes, 3. infiltrative cardiomyopathy, 4. hypertrophic cardiomyopathy, 5. pericardial disease with significant constriction, or 3. active pregnancy, 4. any competing conditions leading to an expected survival of \< 2 years 5. contraindication to vasodilator (regadenoson or adenosine) 6. metallic device or object that poses an magnetic resonance imaging safety hazard 7. metallic device with a high likelihood of non-diagnostic cardiac magnetic resonance images

Conditions

Ischemic Heart Disease (IHD) Cardiac Magnetic Resonance Imaging Myocardial Blood Flow

Locations

  • University of California San Francisco — San Francisco, California, United States
  • UofL Health - Heart Hospital — Louisville, Kentucky, United States
  • Brigham and Women's Hospital — Boston, Massachusetts, United States
  • Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States
  • St. Francis Hospital and Heart Center — Roslyn, New York, United States
  • Atrium Health - Sanger Heart & Vascular Institute — Charlotte, North Carolina, United States
  • Cleveland Clinic — Cleveland, Ohio, United States
  • The Ohio State University — Columbus, Ohio, United States
  • Vanderbilt University Medical Center — Nashville, Tennessee, United States
  • Houston Methodist Hospital — Houston, Texas, United States
  • University of Utah — Salt Lake City, Utah, United States
  • University of Virginia — Charlottesville, Virginia, United States
  • Virginia Commonwealth University — Richmond, Virginia, United States
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record